

Examining the effect of intravenous zoledronic acid on pleural fluid production, breathlessness and quality of life in patients with a malignant pleural effusion

Submission date 29/09/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 29/09/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 22/09/2015	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

The pleura are the two thin membranes around the lungs. Cancer can spread to the pleura or originate there, and may be associated with fluid accumulation called a 'malignant pleural effusion'. This compresses the lungs, causes breathlessness and coughing, and shortens the patient's life expectancy. We commonly manage this problem by inserting a tube called a chest drain to remove the fluid. We can also try to stick the linings of the lung together to take away the space into which fluid can accumulate - this is called 'pleurodesis'. A small permanent drain can also be placed to allow the patient to go home and have fluid drawn off when they are breathless. These three options do not address the underlying problem of the cancer cells causing the excessive fluid production. A drug that reduces fluid production may help patients for whom drainage and pleurodesis are inappropriate or have proved unsuccessful, and may allow us to target malignant pleural effusions early and avoid these invasive procedures.

Zoledronic acid is a drug that is in common use for patients with cancer that has spread to their bones, for bone thinning (osteoporosis) in women following the menopause, and to treat high calcium levels and some other bone disorders. It is given as a drip and can be given as a one off dose or repeatedly at 3-4 weekly intervals. It has effects on cancer cells and particularly their ability to make new blood vessels. It has been shown to reduce the relapse rate in women with breast cancer when added to other usual treatment. Zoledronic acid reduces the growth of two kinds of cancer of the lung lining and also appears to reduce pleural fluid production in mice. The aim of this study is to find out whether the effect seen in mice translates to humans. This study seeks to examine whether zoledronic acid at its currently used dose reduces the progression of pleural tumours and the accumulation of pleural fluid, and therefore improves symptoms in patients with malignant pleural disease.

Who can participate?

Patients aged over 18 with cancer and a malignant pleural effusion.

What does the study involve?

Participants are randomly allocated to be treated with either zoledronic acid or a placebo (dummy) drug.

What are the possible benefits and risks of participating?

Not provided at time of registration.

Where is the study run from?

Southmead Hospital (UK).

When is the study starting and how long is it expected to run for?

August 2010 to June 2013.

Who is funding the study?

Novartis Pharmaceuticals UK Limited (UK).

Who is the main contact?

Dr Amelia Dunscombe

Amelia.Dunscombe@nbt.nhs.uk

Contact information

Type(s)

Scientific

Contact name

Dr Amelia Dunscombe

Contact details

Southmead Hospital

Southmead Road

Westbury-On-Trym

Bristol

United Kingdom

BS10 5NB

-

Amelia.Dunscombe@nbt.nhs.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2009-009134-32

Protocol serial number

8877

Study information

Scientific Title

A double blind randomised controlled trial examining the effect of intravenous zoledronic acid on pleural fluid production, breathlessness and quality of life in patients with a malignant pleural effusion

Study objectives

Malignant pleural disease is common clinical problem, with effusions occurring in 15% of patients diagnosed with cancer during the course of their disease. They indicate a particularly poor prognosis.

Malignant pleural effusions are associated with dyspnoea and recurrent hospital attendances and have a detrimental impact on the quality of life of cancer patients. The most commonly employed management strategy of thoracentesis and talc pleurodesis has suboptimal success rates and patients frequently undergo repeated invasive procedures as a result. These strategies seek to drain pleural fluid and attempt to obliterate the pleural space but do not target the principle problem of excess fluid accumulation. A drug that reduces pleural fluid production would have the potential to improve symptoms in patients with malignant effusions and might have particular utility in the treatment of patients with 'trapped lung' or severe underlying lung disease for whom pleurodesis is relatively contraindicated or indeed for patients with small effusions at presentation where optimum timing of pleurodesis is controversial. There is a wealth of in vitro and in vivo animal and human evidence to suggest that the amino-bisphosphonate, zoledronic acid (already in common clinical use for skeletal indications) has potent anti-angiogenic and anti-tumour effects. Zoledronic acid has been shown to inhibit growth of mesothelioma cells in mice and reduce pleural fluid accumulation in a murine model of pleural adenocarcinoma. The addition of ZA to endocrine therapy in breast cancer has recently been associated with highly significant improvements in disease free and relapse free survival.

This pilot study seeks to inform a large multicentre randomised controlled trial examining the effect of zoledronic acid on pleural tumour progression, pleural fluid accumulation, breathlessness and quality of life as compared to placebo in patients with symptomatic malignant pleural effusions and/or thickening

Ethics approval required

Old ethics approval format

Ethics approval(s)

South West 2 REC, 18/5/2009, ref: 09/H0206/12

Study design

Randomised; Interventional; Design type: Treatment

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Lung Cancer; Disease: Lung (small cell), Lung (non-small cell)

Interventions

Intervention arm = zoledronic acid; control arm = placebo

Zoledronic acid, 4g IV: 2 doses as 21 day intervals; Follow Up Length: 2 month(s); Study Entry : Single Randomisation only

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Zoledronic acid

Primary outcome(s)

Change in gadolinium uptake and washout rate on Dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI); Timepoint(s): 42 days

Key secondary outcome(s)

Change in dyspnoea Visula Analogue Scale (VAS) score; Timepoint(s): 42 days

Completion date

30/06/2013

Eligibility

Key inclusion criteria

1. Malignant pleural thickening with or without pleural effusion with
 - 1.1. Malignant fluid cytology or
 - 1.2. Malignant pleural biopsy histology or
 - 1.3. In the context of clinically proven cancer elsewhere with no alternative cause found for the pleural thickening or effusion
2. Age > 18 years; Target Gender: Male & Female ; Lower Age Limit 18 no age limit or unit specified

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Chemical or surgical pleurodesis in the preceding 30 days
2. Intravenous (IV) bisphosphonate within the past 3 months or ongoing therapy
3. Ongoing dental disease requiring intervention
4. Significant renal failure (calculated creatinine clearance of < 40ml/min)
5. Hypocalcaemia at randomisation
6. Inability to give informed consent
7. Pregnancy or lactation
8. Known allergy to bisphosphonates or excipients in the intervention preparation
9. Life expectancy < 4 months
10. Current or planned chemotherapy (However patients receiving the oral chemotherapy agent, tarceva who have been on it for more than 3 months can be included)
11. Hormone manipulation therapy initiated in the month before trial entry (however patients receiving long term hormone manipulation can be included)
12. Haematological malignancy
13. Age < 18 years (no upper age limit)
- 14/. Severe visual impairment.

Date of first enrolment

02/08/2010

Date of final enrolment

30/06/2013

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Southmead Hospital

Bristol

United Kingdom

BS10 5NB

Sponsor information

Organisation

North Bristol NHS Trust (UK)

ROR

<https://ror.org/036x6gt55>

Funder(s)

Funder type

Industry

Funder Name

Novartis Pharmaceuticals UK Limited

Alternative Name(s)

Novartis UK, NOVARTIS UK LIMITED

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/03/2015		Yes	No
HRA research summary			28/06/2023	No	No